Capecitabine

SKU: orb1308702

Description

Capecitabine is an orally administered antimetabolite prodrug that is enzymatically converted to 5-fluorouracil (5-FU) within tumor cells. Its active metabolites, FdUMP and FUTP, inhibit DNA and RNA synthesis, respectively, making it a key tool for in vitro and in vivo cancer research, particularly in studies of colorectal, breast, and gastric malignancies.

Research Area

Cell Biology, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 154361-50-9
• MW: 359.35
• Purity: 99.37% (May vary between batches)
• Formula: C₁₅H₂₂FN₃O₆
• SMILES: O[C@H]1[C@@H](O[C@H](C)[C@H]1O)N2C(=O)N=C(NC(OCCCCC)=O)C(F)=C2
• Target: Nucleoside Antimetabolite/Analog,DNA/RNA Synthesis,Apoptosis
• Solubility: 5% DMSO+95% Saline:1.8 mg/mL (5.01 mM);PBS:50 mg/mL (139.14 mM);Ethanol:35.9 mg/mL (99.9 mM);DMSO:242 mg/mL (673.44 mM)

Bioactivity

• In Vivo:
  Capecitabine induces apoptosis in a Fas-dependent manner and exhibits toxicity sevenfold higher towards LS174T-c2 cells, which are transfected with thymidine phosphorylase, leading to more pronounced apoptosis. When cultured in the same plate as HepG2 cells, both LS174TWT and LS174T-c2 cells show increased sensitivity to Capecitabine, with IC50 values decreasing from 890 μM when LS174TWT cells are cultured alone to 630 μM when co-cultured with HepG2 cells. Additionally, for the LS174T-C2 subtype co-cultured with HepG2 cells, the IC50 significantly drops from 330±4 μM to 89±6 μM.
  Read more...
• In Vitro:
  When administered to mice with a high propensity for liver metastasis, Capecitabine exhibits inhibitory effects on both the growth and metastatic recurrence of human hepatocellular carcinoma. This phenomenon is attributed to the high expression of platelet-driven endothelial growth factor within the tumors. Compared to 5-FU, UFT, and the intermediate metabolite 5'-DFUR, Capecitabine demonstrates a broader spectrum of anticancer activity against human transplant tumors, which is associated with the tumor levels of dThdPase.
  Read more...
• Cell Research:
  HepG2 and either LS174T WT or LS174T-c2 cells are seeded, respectively, in the top and bottom chambers of 8-well strip membranes in 96-well plates. The exponentially growing cells are exposed to increasing concentrations of capecitabine. The medium is supplemented with 750 ng/mL ZB4 MoAB or 100 ng/mL BR17 MoAB when the latter are used in the experiments. After 72 hours of continuous exposure, LS174T viability is assessed using the classic colorimetric MTT test.(Only for Reference)
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DNASynthesis, DNA Synthesis, DNA/RNA Synthesis, Analog, Apoptosis, Capecitabine, Capecitibine, Capiibine, inhibit, NucleosideAntimetabolite, Nucleoside Antimetabolite/Analog, Nucleoside Antimetabolite, Inhibitor, Thymidine phosphorylase, Xeloda, RNASynthesis, RO 09-1978, RNA Synthesis

Compound Identifiers

PubChem CID

60953